2nd Jul 2020 09:16
(Alliance News) - 4d Pharma PLC on Thursday said its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients hospitalised with Covid-19 is now open to enrolment, and dosing of the first patients is expected shortly.
The AIM-listed pharmaceutical company said the trial is enrolling up to 90 patients admitted to hospital with Covid-19 in the UK. Eligible patients will receive daily oral MRx-4DP0004 or placebo, in addition to standard supportive care.
The primary endpoint of the trial, 4d Pharma said, is the mean change in clinical status score as measured by the World Health Organisation ordinal scale for clinical improvement.
In addition, a number of secondary endpoints assess measures of clinical efficacy including the need for, and duration of, ventilation, in addition to safety and tolerability.
4d Pharma said MRx-4DP0004 is expected to display a favourable safety profile. In an ongoing asthma study it has demonstrated an "excellent" safety profile to date.
"Reducing hyperinflammation, particularly in the lungs, is key to preventing the exacerbation of symptoms associated with more severe Covid-19. 4D pharma has shown MRx-4DP0004 has the ability to target inflammation in the lungs, potentially reducing the respiratory issues central to Covid-19," said Chief Scientific Officer Alex Stevenson.
"Following positive data from the Covid-19 clinical trial, 4d pharma intends to explore the potential utility of MRx-4DP0004 in additional viral infections like influenza," added Stevenson.
4d Pharma shares were trading 1.8% lower in London on Thursday at 40.12 pence each.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L